Zentalis Pharmaceuticals, INC. (ZNTL) — 8-K Filings

8-K Filings (22)

• Zentalis Pharmaceuticals Presents Clinical Data Updates — Apr 17, 2026 Risk: medium
  On April 17, 2026, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing updates on its clinical programs. The company presented data from its Phase 1 st
• 8-K Filing — Apr 9, 2026
• Zentalis Pharmaceuticals Announces Board and Executive Changes — Dec 15, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on December 15, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the comp
• Zentalis Pharmaceuticals Announces Board Changes and Filings — Aug 26, 2025 Risk: medium
  On August 26, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Lori Friedman fr
• Zentalis Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 18, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The filing details
• Zentalis Pharmaceuticals Files 8-K — Jun 2, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing primarily concerns Regulation FD disclosures and fi
• Zentalis Pharmaceuticals Files 8-K — May 20, 2025 Risk: low
  On May 20, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Stat
• Zentalis Pharmaceuticals Files 8-K — Apr 28, 2025 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on April 28, 2025, reporting on events as of April 27, 2025. The filing primarily concerns Regulation FD disclosures
• Zentalis Pharmaceuticals Files 8-K — Mar 17, 2025 Risk: low
  On March 15, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhib
• Zentalis Pharmaceuticals Files 8-K Report — Jan 29, 2025 Risk: low
  On January 29, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with fi
• Zentalis Sells Subsidiary, Focuses on Oncology Pipeline — Jan 28, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on January 22, 2025, that it has entered into a definitive agreement to sell its Zentalis Pharmaceuticals, LLC subsidia
• Zentalis Pharma Appoints New Chief Medical Officer — Nov 13, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on November 12, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer. Dr. Rabin brings extensive experie
• Zentalis Pharmaceuticals Files 8-K Report — Sep 16, 2024 Risk: low
  On September 16, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Other Events, along with
• Zentalis Pharmaceuticals Files 8-K on Shareholder Votes — Jun 21, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain spec
• 8-K Filing — Jun 3, 2024
• Zentalis Pharma Appoints New CMO, Dr. Melissa Johnson — May 29, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. announced on May 24, 2024, the appointment of Dr. Melissa L. Johnson as Chief Medical Officer, effective immediately. Dr. Johnson
• Zentalis Pharmaceuticals Appoints New CMO, Director — Apr 11, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. announced on April 5, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer and the election of Ms. Karen L. Smith
• Zentalis Pharmaceuticals Files 8-K Report — Apr 9, 2024 Risk: low
  On April 9, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibi
• Zentalis Pharma Files 8-K for Financial Results — Feb 27, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report its Results of Operations and Financial Condition, including Financial Statements an
• Zentalis Pharmaceuticals Files 8-K on Bylaw Amendments, Fiscal Year Change — Feb 15, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 12, 2024. The filing indicates amendments to its Ar
• Zentalis Pharma 8-K: Listing, Officer Changes Reported — Jan 25, 2024
  Zentalis Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, reporting events from January 19, 2024. The filing indicates potential issues with continued li
• Zentalis Pharma Files Routine 8-K, Updates Admin Info — Jan 8, 2024
  Zentalis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing is a routine current report, pr

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX